TrialJournal of hematology & oncology2018

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.

Robert W Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.